201 related articles for article (PubMed ID: 34147908)
1. Metal binding 6-arylthio-3-hydroxypyrimidine-2,4-diones inhibited human cytomegalovirus by targeting the pUL89 endonuclease of the terminase complex.
Wang L; Edwards TC; Sahani RL; Xie J; Aihara H; Geraghty RJ; Wang Z
Eur J Med Chem; 2021 Oct; 222():113640. PubMed ID: 34147908
[TBL] [Abstract][Full Text] [Related]
2. Repurposing N-hydroxy thienopyrimidine-2,4-diones (HtPD) as inhibitors of human cytomegalovirus pUL89 endonuclease: Synthesis and biological characterization.
He T; Edwards TC; Majima R; Jung E; Kankanala J; Xie J; Geraghty RJ; Wang Z
Bioorg Chem; 2022 Dec; 129():106198. PubMed ID: 36265353
[TBL] [Abstract][Full Text] [Related]
3. Metal-chelating 3-hydroxypyrimidine-2,4-diones inhibit human cytomegalovirus pUL89 endonuclease activity and virus replication.
Wang Y; Tang J; Wang Z; Geraghty RJ
Antiviral Res; 2018 Apr; 152():10-17. PubMed ID: 29425830
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Human Cytomegalovirus pUL89 Terminase Subunit Blocks Virus Replication and Genome Cleavage.
Wang Y; Mao L; Kankanala J; Wang Z; Geraghty RJ
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881652
[TBL] [Abstract][Full Text] [Related]
5. Hydroxypyridonecarboxylic Acids as Inhibitors of Human Cytomegalovirus pUL89 Endonuclease.
Kankanala J; Wang Y; Geraghty RJ; Wang Z
ChemMedChem; 2018 Aug; 13(16):1658-1663. PubMed ID: 29968426
[TBL] [Abstract][Full Text] [Related]
6. 4,5-Dihydroxypyrimidine Methyl Carboxylates, Carboxylic Acids, and Carboxamides as Inhibitors of Human Cytomegalovirus pUL89 Endonuclease.
He T; Edwards TC; Xie J; Aihara H; Geraghty RJ; Wang Z
J Med Chem; 2022 Apr; 65(7):5830-5849. PubMed ID: 35377638
[TBL] [Abstract][Full Text] [Related]
7. 8-Hydroxy-1,6-naphthyridine-7-carboxamides as Inhibitors of Human Cytomegalovirus pUL89 Endonuclease.
Jung E; Majima R; Edwards TC; Soto-Acosta R; Geraghty RJ; Wang Z
ChemMedChem; 2022 Sep; 17(17):e202200334. PubMed ID: 35879245
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting HCMV pUL89-C Endonuclease with Metal-Binding Compounds.
Jagtap AD; Geraghty RJ; Wang Z
J Med Chem; 2023 Oct; 66(20):13874-13887. PubMed ID: 37827528
[TBL] [Abstract][Full Text] [Related]
9. FRET-based assay using a three-way junction DNA substrate to identify inhibitors of human cytomegalovirus pUL89 endonuclease activity.
Wang Y; Geraghty RJ
Eur J Pharm Sci; 2019 Jan; 127():29-37. PubMed ID: 30342172
[TBL] [Abstract][Full Text] [Related]
10. New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc.
Champier G; Hantz S; Couvreux A; Stuppfler S; Mazeron MC; Bouaziz S; Denis F; Alain S
Antivir Ther; 2007; 12(2):217-32. PubMed ID: 17503664
[TBL] [Abstract][Full Text] [Related]
11. The terminase subunits pUL56 and pUL89 of human cytomegalovirus are DNA-metabolizing proteins with toroidal structure.
Scheffczik H; Savva CG; Holzenburg A; Kolesnikova L; Bogner E
Nucleic Acids Res; 2002 Apr; 30(7):1695-703. PubMed ID: 11917032
[TBL] [Abstract][Full Text] [Related]
12. Identification of Small Molecule Inhibitors of Human Cytomegalovirus pUL89 Endonuclease Using Integrated Computational Approaches.
Almehmadi M; Haq IU; Alsaiari AA; Alshabrmi FM; Abdulaziz O; Allahyani M; Aladhadh M; Shafie A; Aljuaid A; Alotaibi RT; Ullah J; Alharthi NS
Molecules; 2023 May; 28(9):. PubMed ID: 37175348
[TBL] [Abstract][Full Text] [Related]
13. Targeting the terminase: An important step forward in the treatment and prophylaxis of human cytomegalovirus infections.
Gentry BG; Bogner E; Drach JC
Antiviral Res; 2019 Jan; 161():116-124. PubMed ID: 30472161
[TBL] [Abstract][Full Text] [Related]
14. Identification of influenza endonuclease inhibitors using a novel fluorescence polarization assay.
Baughman BM; Jake Slavish P; DuBois RM; Boyd VA; White SW; Webb TR
ACS Chem Biol; 2012 Mar; 7(3):526-34. PubMed ID: 22211528
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a novel series of inhibitors of human cytomegalovirus primase.
Cushing TD; Adrian J; Chen X; DiMaio H; Doughan B; Flygare J; Liang L; Mayorga V; Miao S; Mellon H; Peterson MG; Powers JP; Spector F; Stein C; Wright M; Xu D; Ye Q; Jaen J
Bioorg Med Chem Lett; 2006 Sep; 16(18):4879-83. PubMed ID: 16814545
[TBL] [Abstract][Full Text] [Related]
16. Mutual Interplay between the Human Cytomegalovirus Terminase Subunits pUL51, pUL56, and pUL89 Promotes Terminase Complex Formation.
Neuber S; Wagner K; Goldner T; Lischka P; Steinbrueck L; Messerle M; Borst EM
J Virol; 2017 Jun; 91(12):. PubMed ID: 28356534
[TBL] [Abstract][Full Text] [Related]
17.
Ghassabian H; Falchi F; Timmoneri M; Mercorelli B; Loregian A; Palù G; Alvisi G
Viruses; 2021 May; 13(5):. PubMed ID: 34065234
[TBL] [Abstract][Full Text] [Related]
18. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.
Piret J; Boivin G
Antiviral Res; 2019 Mar; 163():91-105. PubMed ID: 30690043
[TBL] [Abstract][Full Text] [Related]
19. Insight into the structure of the pUL89 C-terminal domain of the human cytomegalovirus terminase complex.
Couvreux A; Hantz S; Marquant R; Champier G; Alain S; Morellet N; Bouaziz S
Proteins; 2010 May; 78(6):1520-30. PubMed ID: 20099308
[TBL] [Abstract][Full Text] [Related]
20. The human cytomegalovirus UL51 protein is essential for viral genome cleavage-packaging and interacts with the terminase subunits pUL56 and pUL89.
Borst EM; Kleine-Albers J; Gabaev I; Babic M; Wagner K; Binz A; Degenhardt I; Kalesse M; Jonjic S; Bauerfeind R; Messerle M
J Virol; 2013 Feb; 87(3):1720-32. PubMed ID: 23175377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
